Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap

Cardiovascular disease (CVD) remains the leading cause of death in women globally. Younger women (<55 years of age) who experience MI are less likely to receive guideline-directed medical therapy (GDMT), have a greater likelihood of readmission and have higher rates of mortality than similarly ag...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aarti Thakkar, Anandita Agarwala, Erin D Michos
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/cf51f5baefdf4743a6c4acc3d74e9998
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf51f5baefdf4743a6c4acc3d74e9998
record_format	dspace
spelling	oai:doaj.org-article:cf51f5baefdf4743a6c4acc3d74e99982021-12-04T16:05:17ZSecondary Prevention of Cardiovascular Disease in Women: Closing the Gap10.15420/ecr.2021.241758-37641758-3756https://doaj.org/article/cf51f5baefdf4743a6c4acc3d74e99982021-11-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2021.24https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Cardiovascular disease (CVD) remains the leading cause of death in women globally. Younger women (<55 years of age) who experience MI are less likely to receive guideline-directed medical therapy (GDMT), have a greater likelihood of readmission and have higher rates of mortality than similarly aged men. Women have been under-represented in CVD clinical trials, which limits the generalisability of results into practice. Available evidence indicates that women derive a similar benefit as men from secondary prevention pharmacological therapies, such as statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, icosapent ethyl, antiplatelet therapy, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Women are less likely to be enrolled in cardiac rehabilitation programs than men. Mitigating risk and improving outcomes is dependent on proper identification of CVD in women, using appropriate GDMT and continuing to promote lifestyle modifications. Future research directed at advancing our understanding of CVD in women will allow us to further develop and tailor CVD guidelines appropriate by sex and to close the gap between diagnoses, treatment and mortality.Aarti ThakkarAnandita AgarwalaErin D MichosRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Aarti Thakkar Anandita Agarwala Erin D Michos Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
description	Cardiovascular disease (CVD) remains the leading cause of death in women globally. Younger women (<55 years of age) who experience MI are less likely to receive guideline-directed medical therapy (GDMT), have a greater likelihood of readmission and have higher rates of mortality than similarly aged men. Women have been under-represented in CVD clinical trials, which limits the generalisability of results into practice. Available evidence indicates that women derive a similar benefit as men from secondary prevention pharmacological therapies, such as statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, icosapent ethyl, antiplatelet therapy, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Women are less likely to be enrolled in cardiac rehabilitation programs than men. Mitigating risk and improving outcomes is dependent on proper identification of CVD in women, using appropriate GDMT and continuing to promote lifestyle modifications. Future research directed at advancing our understanding of CVD in women will allow us to further develop and tailor CVD guidelines appropriate by sex and to close the gap between diagnoses, treatment and mortality.
format	article
author	Aarti Thakkar Anandita Agarwala Erin D Michos
author_facet	Aarti Thakkar Anandita Agarwala Erin D Michos
author_sort	Aarti Thakkar
title	Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
title_short	Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
title_full	Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
title_fullStr	Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
title_full_unstemmed	Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
title_sort	secondary prevention of cardiovascular disease in women: closing the gap
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/cf51f5baefdf4743a6c4acc3d74e9998
work_keys_str_mv	AT aartithakkar secondarypreventionofcardiovasculardiseaseinwomenclosingthegap AT ananditaagarwala secondarypreventionofcardiovasculardiseaseinwomenclosingthegap AT erindmichos secondarypreventionofcardiovasculardiseaseinwomenclosingthegap
_version_	1718372702398447616

Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap

Ejemplares similares